Author + information
- Received August 8, 2017
- Revision received December 5, 2017
- Accepted January 4, 2018
- Published online April 2, 2018.
- Abdallah El Sabbagh, MD,
- Yogesh N.V. Reddy, MBBS and
- Rick A. Nishimura, MD∗ ()
- ↵∗Address for correspondence:
Dr. Rick A. Nishimura, Department of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
Mitral valve regurgitation (MR) is the most common valvular heart disease. Primary MR is a disease of the mitral valve apparatus, whereas secondary MR is a disease of the left ventricle. Diagnosing and managing MR is often challenging and requires a structured approach, integrating findings on history, physical examination, and imaging. Decisions regarding treatment depend on knowledge of the etiology, natural history, and outcome of interventions for these patients with mitral valve disease. The optimal timing of intervention requires a comprehensive 2-dimensional and Doppler echocardiogram in each patient to determine the cause of the mitral valve disease, the severity of the regurgitation, and the effect of the volume overload on the left ventricle, as well as determining if a durable valve repair can be performed. Advances in both surgical and catheter-based therapies have resulted in recommendations for lower thresholds for operation and extension of interventional treatments to the older, sicker population of patients with MR. The current review discusses the pathophysiological rationale for current diagnostic and management strategies in MR.
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received August 8, 2017.
- Revision received December 5, 2017.
- Accepted January 4, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.